Can blockchain transform healthcare IT?
http://dlvr.it/QlpltX https://t.co/A9L1uzDtJS
There is a
#reproducibility #crisis in #science.
We have the solution you need at a cost you can afford.
Find our more from TED.
https://www.youtube.com/watch?v=FpCrY7x5nEE
#MyIRE #Reproducibility #Science #OpenScience #MYR
What if there was a "Good Housekeeping Seal of Approval" for
#ClinicalTrials that return
#clinicalresearch results to #patients?
#DPharm2018 @CraigLipset @hmkyale @andreas_koe @pfizer @JanssenUS #DCRIResearchTogether
How could
#blockchain be used in #healthcare? We've identified six areas that may stand to benefit the most, affecting all sectors of the healthcare industry. Take a look:
https://pwc.to/2IlGNEK
The Irreproducibility Crisis of Modern Science: Causes, Consequences, and the Road to Reform
Read our commercial proposal via the National Association of Scholars:
https://www.nas.org/projects/irreproducibility_report/what_others_say
#MyIRE #Science #Reproducibility #MYR
"If you have an
#apple and I have an apple and if we exchange these apples then you and I will still each have one apple. But if you have an
#idea and I have an idea and we exchange these ideas, then each of us will have two ideas" -George Bernard Shaw #collaboration
“You need to worry about [data integrity] from all levels of the supply chain,” she said. “Once there are data integrity lapses, you know there are other things you don’t know.” -Sarah Barkow, FDA
https://www.raps.org/news-and-articles/news-articles/2018/9/data-integrity-a-top-concern-for-manufacturers-fd?feed=Regulatory-Focus
#MyIRE #ClinicalTrials #Medicine #Reproducibility #MYR
HI JOURNALISTS
just a nudge to say: if any individual university or company is giving you reasons why it's okay for them to have poor compliance with the EU rules on reporting trial results, I'm available all day and night to read/respond to their comments.
hello@ebmdatalab.net
https://twitter.com/bengoldacre/status/1039899779340349441
NHCT (NanoHealthCare Token)
@NHCToken
http://nhct.io/ is a blockchain based healthcare ecosystem which aims to introduce the concept of “Total Health.” Telegram:
https://t.me/NanoHealth https://twitter.com/NHCToken/status/1033968100675268608
DAILY TIP: What are Future Trends in #HealthCare? Watch
#AskTheCEO with @IrmaRaste
#CEO @eViRaHealth timestamp [10:00]
#IoMT #IoT #AI #Blockchain @davidhoulding @evankirstel
https://buff.ly/2ONOB4c https://t.co/NW8dd2t0t0
Blockchain To Bring More Wealth In Healthcare Industry
https://buff.ly/2NqLT7J #Healthcare #Wealth #Blockchain https://t.co/S1meTYid3h
"European science funders ban grantees from publishing in paywalled journals."
You read that correctly: No more articles in @sciencemagazine @nature @NEJM @JAMA_current, etc. for European investigators from 11 countries.
A game changer for #OpenScience.
http://www.sciencemag.org/news/2018/09/european-science-funders-ban-grantees-publishing-paywalled-journals?rss=1
MyIRE was featured at Chain Reaction Blockchain Healthcare Summit, the first “evidence-based” blockchain healthcare summit. We participated in an interactive panel entitled Blockchain for Increased Trust in Clinical Trials.
My Integrated Research Environment (“MyIRE”) is a novel technology that we believe will increase clinical trial throughput and simultaneously increase their process and data integrity. As a comprehensive scientific software platform, MyIRE is designed to provide end-to-end support for clinical trials supported by blockchain-enabled features to facilitate data integrity and transferability, as well as to confirm consistency of protocol execution, and therefore generate improved study results through reproducibility. We present a disruptive economic model showing how we anticipate this result will be achieved for a fraction of the cost associated with, and resulting from, using existing tools. We believe this combination of a novel technology and the proposed economic model provides a compelling case for a new cryptocurrency token.
Our four-node proof of concept infrastructure consists of Network, Infrastructure, Compute, and Storage nodes. We used non-specialty, commercially available hardware with machines consuming 50% maximum capacity in terms of processing, RAM, and storage. Power optimization was not taken into account. Rather, the potential for maximal participation was targeted by optimizing for mass commercial availability. Control plane segregation, separation of concerns, and principles of least privilege were three factors also considered in our design.
MyIRE presented a seminar entitled “Building Blocks of Rapidly Iterable, Reproducible Clinical Trials” to the CBER HIVE Team.
**Abstract:**
Easy to use tools are revolutionizing medical innovation, but the "telephone game of research software tools" has implications on participant privacy and scientific integrity. Increasing expectations for privacy and integrity can be achieved by harnessing the power of existing open technologies. MyIRE will present strategies for successful adoption of open technologies and case studies of building blocks for rapidly iterable, reproducible clinical trials.
Internal validity and end-user acceptance of individual modules was tested via deployment across multiple organizations. We put into place legally binding contracts for decentralization of those modules with differential privacy restrictions that may be regulated. Module provenance and history were stored with the capacity for each organization to verify integrity. Modules were stored separately from data owned by each organization, so data integrity and module integrity can be verified independently.
MyIRE presented a case study of blockchain technology combined with easy to use tools and its impact on research integrity. We also demonstrated how this approach empowers doctors to participate in research as part of their daily practice.
Internal validity and end-user acceptance of individual modules was tested via deployment across multiple organizations. We put into place legally binding contracts for decentralization of those modules with differential privacy restrictions that may be regulated. Module provenance and history were stored with the capacity for each organization to verify integrity. Modules were stored separately from data owned by each organization, so data integrity and module integrity can be verified independently.
Modules comprising the process of creating a hypothesis, testing it, and publishing the results were composed into projects. Multiple projects were run through the system. The results of one of the projects are ready to submit for peer review with the expectation that the results will be published in a journal with a reference to MyIRE. That project will be repeatable, in the manner described above, by anyone and anywhere -- thereby minimizing instrumental bias. The project was forked to a different node of the same specification. Alterations were made to individual data collection elements within the forked study. Interfaces remained interoperable and the project was auto-documenting. Underlying data was not transferred between machines.
Mark Graves, Jr. is one of our founders, and the developer of the MyIRE platform. Mr. Graves has served as our chief executive officer, president and chief technical officer since the company was founded in December 2015. Mr.Graves began a clinical research career while still a teenager and has years of experience designing and delivering clinical and preclinical trials. He earned a bachelor’s degree from Northwestern University and attended Northwestern University’s Feinberg School of Medicine for two years. Mr. Graves brings to the company unique perspective and insights regarding the strategic and operational opportunities and challenges, economic and industry trends, and competitive and financial positioning of our business.
Mark Graves Sr., MD is one of our founders. Dr. Graves is an internist, and is affiliated with Deaconess Hospital in Evansville, IN. He received his medical degree from University of Pittsburgh School of Medicine and has been in practice for more than 20 years. Dr. Graves is a clinical investigator and has worked on more than 100 clinical trials of medications and devices. Dr. Graves has experience in designing trials, writing informed consents, writing protocols, interacting with the IRB, following regulations, and managing and analyzing trial data. Dr. Graves brings to the company significant operational, regulatory, and financial experience as a physician and clinical investigator.
Gregory Folz, CCRP is one of our founders. Mr. Folz is the Administrative Director of Research for the Deaconess Research Institute, where he has overseen the conduct of more than 800 clinical trials. Mr. Folz was recently recognized as “2018 Top 20 Innovators” in the clinical research industry; and is the recipient of the 2016 SCRS Site Tank Award for Innovation, and a finalist for the Society for Clinical Research Site’s 2015 Innovation Award for patient recruitment. Mr. Folz serves as a national consultant and speaker on the development of clinical research operations and business structures and has assisted more than a dozen US hospital systems, networks, and physician groups on the strategic growth of their clinical research initiatives. Mr.Folz brings a wealth of clinical trial experience and relationships to the company.
MyIRE, Inc. is a Delaware C Corp.